August 23, 2021 August 23, 2021 NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research July 22, 2021 July 22, 2021 NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration July 7, 2021 July 7, 2021 NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors July 1, 2021 July 1, 2021 NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases May 24, 2021 May 24, 2021 NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH March 2, 2021 March 2, 2021 - NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer February 9, 2021 Feb 9, 2021 - NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition January 12, 2021 Jan 12, 2021 - NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology January 6, 2021 Jan 5, 2021 - NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock December 9, 2020 Dec 9, 2020 - NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors November 13, 2020 Nov 13, 2020 - NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 October 19, 2020 Oct 19, 2020 - NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, a Novel Dual Antagonist Antibody August 31, 2020 Aug 29, 2020 - NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study of Aldafermin at Digital International Liver Congress (ILC) 2020 and Enrollment Completed in Phase 2b ALPINE Study July 27, 2020 July 27, 2020 - NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) June 8, 2020 June 8, 2020 - Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis May 8, 2020 May 8, 2020 - AtriCure Announces Results from CONVERGE IDE Clinical Trial February 24, 2020 February 24, 2020 - NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study of Aldafermin in NASH Patients February 11, 2020 February 11, 2020 - NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS) February 3, 2020 February 3, 2020 - Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis January 7, 2020 January 7, 2020 - AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol Older Posts Contact Prospect Venture Partners: Address: 525 University Ave., Suite 1350 Palo Alto, CA 94301 Phone: (650) 327-8800 Prospect Ventures Funds: Prospect Venture Partners I Prospect Venture Partners II Prospect Venture Partners III Connect with Prospect Ventures: Prospect Ventures on LinkedIn Prospect Ventures on Crunchbase Prospect Ventures on Bloomberg Prospect Ventures on CB Insights Prospect Ventures on Palico Prospect Ventures on Index.co Prospect Bio Ventures © 2018 - Prospect Venture Partners.. All Rights Reserved No content on this site may be republished or reprinted without written permission from Prospect Venture Partners